Ann: Positive FDA Pre-IND meeting guides IHL-675A development, page-134

Just bringing up this little tidbit of information again from the FDA announcement.....

• The combined annual global market size of the indications being targeted by Incannex with IHL-675A is
  over US$125B, so we consider the economic potential, as well as the benefit to patients over
  incumbent treatments, to be enormous”.

Joel didn't hold back when discussing the direction that IHL is heading with this New Drug Application!

Certainly looking forward to getting the Phase 1 clinical safety trial underway in the near term.